Joris Zimmermann

Richard Vosser

Chiara Montironi

Jonathan Chang

Michael Nedelcovych

- Molecular Partners AG reported significant progress in the first half of **2025**, advancing its lead clinical programs **MP0533** and **MP0712**, with an IND filing and Phase 1 trial for **MP0712** anticipated by the end of **2025**.  **[1745114_7f294fc28c85450c85b7c20d996105b6]** 
- The company expanded its strategic partnership with Orano Med to include up to **10** targeted radiotherapy programs.  **[1745114_7f294fc28c85450c85b7c20d996105b6]** 
- Molecular Partners maintains a robust cash position of approximately **CHF 114 million**, securing its operational runway into **2028**, and undertook a workforce reduction to enhance efficiency.  **[1745114_7f294fc28c85450c85b7c20d996105b6]** 
- Martin Steegmaier, Ph.D., was appointed Chief Scientific Officer, though the stock has a neutral analyst rating due to ongoing financial challenges, including negative profitability margins.  **[1745114_7f294fc28c85450c85b7c20d996105b6]**

MOLECULAR PARTNERS (MOLN)